Skip to main content
Acta Crystallographica Section F: Structural Biology Communications logoLink to Acta Crystallographica Section F: Structural Biology Communications
. 2014 Jan 21;70(Pt 2):196–199. doi: 10.1107/S2053230X13033967

Preliminary X-ray diffraction analysis of CfaA, a molecular chaperone essential for the assembly of CFA/I fimbriae of human enterotoxigenic Escherichia coli

Rui Bao a, Lothar Esser a, Steven Poole b, Annette McVeigh b, Yu-xing Chen c, Stephen J Savarino b,d, Di Xia a,*
PMCID: PMC3936439  PMID: 24637755

The molecular chaperone CfaA plays a critical role in the bioassembly of the surface-adhesive CFA/I fimbriae of enterotoxigenic E. coli. Purified CfaA was crystallized and the phase solution was determined by the multiple isomorphous replacement coupled with anomalous scattering method.

Keywords: CFA/I fimbriae, molecular chaperones

Abstract

Understanding of pilus bioassembly in Gram-negative bacteria stems mainly from studies of P pili and type 1 fimbriae of uropathogenic Escherichia coli, which are mediated by the classic chaperone–usher pathway (CUP). However, CFA/I fimbriae, a class 5 fimbria and intestinal colonization factor for enterotoxigenic E. coli (ETEC), are proposed to assemble via the alternate chaperone pathway (ACP). Both CUP and ACP fimbrial bioassembly pathways require the function of a periplasmic chaperone, but their corresponding proteins share very low similarity in primary sequence. Here, the crystallization of the CFA/I periplasmic chaperone CfaA by the hanging-drop vapor-diffusion method is reported. X-ray diffraction data sets were collected from a native CfaA crystal to 2 Å resolution and to 1.8 and 2.8 Å resolution, respectively, from a lead and a platinum derivative. These crystals displayed the symmetry of space group C2, with unit-cell parameters a = 103.6, b = 28.68, c = 90.60 Å, β = 119.7°. Initial phases were derived from multiple isomorphous replacement with anomalous scattering experiments using the data from the platinum and lead derivatives. This resulted in an interpretable electron-density map showing one CfaA molecule in an asymmetric unit. Sequence assignments were aided by anomalous signals from the heavy-atom derivatives. Refinement of the atomic model of CfaA is ongoing, which is expected to further understanding of the essential aspects and allowable variations in tertiary structure of the greater family of chaperones involved in chaperone–usher mediated bioassembly.

1. Introduction  

The chaperone–usher pathway (CUP) is an evolutionarily conserved mechanism for surface fimbria and/or fibril biogenesis of many Gram-negative bacteria (Nuccio & Bäumler, 2007 ▶). It requires a minimum of three components: a structural pilin subunit that is capable of polymerizing into bacterial surface fimbriae/fibrils, a periplasmic chaperone that stabilizes pilin subunits and escorts them to the outer membrane for assembly, and an outer membrane usher that orchestrates ordered tip-to-base assembly (Choudhury et al., 1999 ▶; Bao et al., 2013 ▶; Kuehn et al., 1993 ▶). Bacterial fimbriae or pili, also referred to as colonization factors (CFs; Evans et al., 1975 ▶), are essential virulence factors for pathogenesis, and to date over 22 different CFs have been identified for enterotoxigenic Escherichia coli (ETEC; Gaastra & Svennerholm, 1996 ▶; Isidean et al., 2011 ▶). The colonization factor antigen I (CFA/I) fimbriae of ETEC, a major cause of diarrhea in travelers to and in young children in resource-limited countries (Huilan et al., 1991 ▶; Wennerås & Erling, 2004 ▶), are the most prevalent surface-adhesive organelles among isolated ETEC field strains (Black, 1990 ▶). CFA/I fimbria is an archetype of a family (class 5) of eight related but serologically distinct fimbriae (Anantha et al., 2004 ▶) that share similar genetic and biochemical features and use a proposed mechanism dubbed the ‘alternate chaperone pathway’ (ACP) for assembly (Sakellaris & Scott, 1998 ▶; Sakellaris et al., 1996 ▶; Soto & Hultgren, 1999 ▶). Included in the class 5 fimbriae are coli surface antigen 1 (CS1), CS2, CS4, CS14, CS17, CS19 and the putative CF O71 (PCFO71). CFA/I biogenesis requires four protein components, a major (CfaB) and a minor (CfaE) structural subunit and two assembly proteins: the chaperone (CfaA) and the usher (CfaC).

The bioassembly of CFA/I fimbriae is initiated by the attachment of the chaperone/minor pilin (CfaA/CfaE) heterodimer to the usher protein CfaC at the outer membrane assembly site followed by cyclic incorporation of the major pilin (CfaB) (Poole et al., 2007 ▶; Li et al., 2007 ▶, 2009 ▶). Both pilin subunits, CfaE and CfaB, require the chaperone CfaA for folding and stability and are incorporated into the pilus by the donor-strand exchange mechanism (Sauer et al., 1999 ▶; Choudhury et al., 1999 ▶; Kuehn et al., 1993 ▶). The ability of chaperones to provide stability to individual pilin subunits is by means of donor-strand complementation, which was revealed by crystallographic analyses of chaperone–pilin complexes from P pili and type 1 fimbriae of uropathogenic E. coli and from fraction 1 (F1) antigen of Yersinia pestis, leading to the classification of FGS and FGL chaperones (Chapman et al., 1999 ▶). In spite of these advances, the use of ACP for biogenesis of the class 5 fimbriae implies structural and functional distinctions for chaperone proteins of the class 5 fimbriae, and to date there is no structural information available for any of these chaperones. Here, we report the crystallization and preliminary X-ray diffraction analysis for the chaperone CfaA of CFA/I fimbriae. The detailed structural knowledge of the chaperone–subunit interaction is expected to further our understanding of the assembly process of CFA/I fimbriae, which is expected to impact the development of potential therapeutic interferences.

2. Materials and methods  

2.1. Cloning, expression and purification of recombinant CfaA  

The expression plasmid pET24a-cfaA(his)6 was constructed by incorporating the full-length cfaA coding region (Gene ID 12796579) derived from wild-type plasmid pNTP513 (Hibberd et al., 1991 ▶), adding an LEHHHHHH purification tag C-terminally and transforming into E. coli strain BL21(DE3) (New England Biolabs, Ipswich, Massachusetts, USA). The resultant E. coli cells were grown in Terrific broth (Research Products International, Mount Prospect, Illinois, USA) in the presence of 50 µg ml−1 kanamycin at 310 K to an optical density of 1.5 at 600 nm, at which point the culture was cooled to 291 K and CfaA expression was induced by adding IPTG to a final concentration of 0.8 mM. After a further 16 h of incubation at 291 K, cells were collected by centrifugation at 4000g for 25 min. The cell pellets were resuspended in a hypertonic buffer consisting of 60 mM Tris–HCl pH 7.5, 20% glycerol for 10 min followed by another centrifugation. The periplasmic extracts were prepared by resuspending the cell pellet in an ice-cold hypotonic buffer consisting of 5 mM MgCl2, 5 mM CaCl2, 20 mM Tris–HCl pH 7.5, 50 mM NaCl followed by high-speed centrifugation at 16 000g for 30 min. The supernatant was loaded onto an Ni–NTA Superflow column (Qiagen, Germantown, Maryland, USA) pre-equilibrated with binding buffer (25 mM Tris–HCl pH 7.5, 100 mM NaCl) plus 20 mM imidazole. His-tagged CfaA was eluted with the same binding buffer plus 300 mM imidazole. As a last step, size-exclusion chromatography was used to further purify CfaA and the resulting CfaA was concentrated to 10 mg ml−1 with an Amicon Ultra-15 centrifugal filtration device with 10 kDa molecular-weight cutoff (Millipore, Millerica, Massachusetts, USA).

2.2. Crystallization, preparation of heavy-metal derivatives, X-ray diffraction image collection and data reduction  

Crystallization of purified CfaA was initiated with a robotic screen of 576 crystallization conditions using the vapor-diffusion hanging-drop method in 96-well plate format (Greiner Bio-One, Monroe, North Carolina, USA), in which 150 nl commercial crystallization solution (Crystal Screen HT, Index HT, PEG/Ion HT, SaltRx HT, Hampton Research, Aliso Viejo, California, USA; Structure Screen 1 and 2 HT, Molecular Dimensions, Altamonte Springs, Florida, USA; Wizard I and II, Emerald BioSystems, Bedford, Massachusetts, USA) were admixed with 150 nl protein solution (10 mg ml−1) using a robotic liquid dispenser (Mosquito, TTP LabTech, England) and incubated at 293 K over 60 µl reservoir solution. Optimization of initial hits was carried out manually with Linbro plates (Hampton Research, Aliso Viejo, California, USA) by mixing 2–4 µl protein solution with 2 µl optimized well solution. Crystals usually appeared after 5 d of incubation at 293 K. Heavy-metal derivatives were prepared by soaking native crystals in well solution plus 2 mM K2PtCl4 or 15 mM lead(II) acetate overnight. Native and derivatized crystals were stabilized by cross-linking using 0.15% glutaraldehyde solution in a vapor-diffusion setup (Lusty, 1999 ▶). Cross-linked crystals were further treated with a buffer containing 30% glycerol prior to flash-cooling in liquid propane, which allows a faster rate of cooling (Teng & Moffat, 1998 ▶).

Diffraction images were collected on a MAR CCD 225 detector at the SER-CAT beamline 22D of the Advanced Photon Source (APS), Argonne National Laboratory (ANL). Data reduction including indexing, integration and scaling was performed using the HKL-2000 package (Otwinowski & Minor, 1997 ▶). The initial phase was solved experimentally by multiple isomorphous replacement coupled with anomalous scattering (MIRAS) using SOLVE/RESOLVE as implemented in the PHENIX suite (Terwilliger, 2003 ▶; Adams et al., 2010 ▶).

3. Results and discussion  

3.1. Protein purification, crystallization, cryoprotection and preliminary X-ray diffraction analysis  

The chaperone protein CfaA of the human-specific ETEC CFA/I fimbriae was cloned and its C-terminus was extended with a hexahistidine tag via a dipeptide linker (LE), resulting in the expression plasmid pET24a-cfaA(his)6. The protein was overexpressed in E. coli and was then purified to homogeneity by nickel-affinity chromatography followed by size-exclusion chromatography. The protein yield was about 8 mg per litre of E. coli culture. The purity of the protein preparation was checked by SDS–PAGE (Fig. 1 ▶). Both N-terminal sequencing and mass-spectrometric analysis of the purified protein confirmed the cleavage of the signal peptide. Mature CfaA with a C-­terminal hexahistidine tag has 227 residues with a molecular weight of 26 kDa. Purified CfaA was concentrated to approximately 10 mg ml−1, with which crystallization screens were performed robotically using commercial crystallization screening kits at 291 K. Three conditions yielded promising hits (A11 and F10 from Hampton Research Index HT and A8 from Emerald Wizard I and II HT). CfaA tends to form crystal clusters (Fig. 2 ▶ a). Optimization of initial hits led to the final conditions (22% PEG 3350, 200 mM NaCl, 100 mM MES pH 5.3) that allowed reproducible crystallization of single crystals of better morphology growing from large crystal clusters (Fig. 2 ▶ b).

Figure 1.

Figure 1

SDS–PAGE of purified recombinant CfaA. The right lane contains molecular-mass marker (labelled in kDa).

Figure 2.

Figure 2

(a) Clusters of CfaA crystals from initial crystallization screening. (b) CfaA crystals after optimization.

Flash-cooling of CfaA crystals with liquid nitrogen led to an increase in the crystal mosaic spread and poor diffraction, which prompted a search for cryoprotection conditions that could minimize the increase in mosaic spread, improve diffraction quality and enhance compatibility with the subsequent heavy-metal-derivatization process. We found that cross-linking with glutaraldehyde was particularly helpful to provide mechanical strength to CfaA crystals for cryoprotection. After cross-linking, CfaA crystals were treated with a cryoprotectant consisting of 20% PEG 3350, 0.15 M NaCl, 70 mM MES pH 5.3, 30% glycerol before flash-cooling in liquid propane.

Crystals of CfaA typically diffracted X-rays to 1.8 Å resolution (Fig. 3 ▶) using synchrotron radiation. The diffraction patterns are consistent with the symmetry of a C-centered monoclinic crystal lattice (space group C2). The native crystals had unit-cell parameters a = 103.6, b = 28.68, c = 90.60 Å, β = 119.7°. Calculation of the Matthews coefficient (V M) suggested the presence of one (V M = 2.25 Å3 Da−1) CfaA molecule per asymmetric unit (Matthews, 1968 ▶).

Figure 3.

Figure 3

Diffraction image from an optimized CfaA crystal. The diffraction resolution at the edge of the image is about 1.8 Å.

3.2. Search for heavy-atom-derivatized CfaA crystals  

Attempts to solve the crystallographic phase problem by the molecular-replacement method failed to yield a correct solution owing to a lack of suitable search models. Thus, other experimental phasing approaches must be adopted. The presence of a single methionine residue (Met3) at the N-terminus of the mature CfaA sequence precludes the use of straightforward SeMet derivatization for phasing. Our first approach was to dope heavy-metal compounds directly into CfaA crystals. A large number of compounds such as Hg(CH3COO)2, HgCl2, K2Pt(NO2)4, K2HgI4, AgNO3, K2PtCl4, Pb(CH3COO)2, K2PtCl6 and (CH3)3Pb(CH3COO) were tested and most of them led to a decline in diffraction quality.

In a separate approach, attempts were made to introduce methionine mutations into the CfaA, in which we aligned eight sequences of chaperone proteins from the class 5 family fimbriae and constructed two mutants based on the principle of conservative substitution of hydrophobic residues. One mutant contained four substitutions (I4M, L213M, I214M and L216M) and another had two mutations (I51M and L190M), all based on the numbering of the mature protein sequence. E. coli cells bearing mutant constructs grew slowly and had considerably lower expression levels of CfaA.

In the meantime, the search for stabilization conditions led to a buffer solution (22% PEG 3350, 0.2 M NaCl, 0.1 M MES pH 5.3) in which CfaA crystals appeared to be stable. Heavy-atom soaking into stabilized CfaA crystals was repeated at different heavy-metal concentrations and for various lengths of time. These crystals were then cross-linked and cryoprotected. Diffraction data sets were collected and analyzed for potential derivatives. Two data sets turned out to be isomorphous derivatives to the native data set: one from overnight soaking with 2 mM K2PtCl4 and the other from soaking with 15 mM Pb(CH3COO)2.

3.3. Phase determination  

A native crystal diffracted X-rays to better than 2 Å resolution, and the resulting data set was processed to 2.07 Å resolution with an R merge of 6.6% (Table 1 ▶). As many as 12 diffraction data sets were collected from various heavy-metal-compound-soaked crystals, but only two were useful for phasing (Tables 1 ▶ and 2 ▶). One data set was obtained from a lead-derivatized crystal at 1.77 Å resolution and a second data set was obtained from a crystal treated with a platinum compound to 2.8 Å resolution (Table 1 ▶ and 2 ▶). The similarities in unit-cell parameters between derivative and native crystals (Table 1 ▶) and the small isomorphous R factors (R iso) of 0.24 and 0.30 for the platinum and lead derivatives, respectively, indicated that both derivatives were relatively isomorphous to the native data set. Both derivative data sets and the native data set were used for MIRAS phasing. Two and one metal-binding sites were identified with reasonable occupancies for the Pb and Pt derivatives, respectively, giving rise to an overall figure of merit of 0.49 in the resolution range between 10.22 and 2.89 Å. Phase improvement by density modification and phase extension was subsequently carried out, producing a high-quality electron-density map with clearly recognizable features of a protein molecule suitable for automated chain tracing. The Pb and Pt data sets were also used to compute anomalous difference Fourier maps with phase information from the improved density-modified MIRAS phases. Residues with heavy-atom attachment were unambiguously identified and were helpful in sequence assignment in model building, which is currently in progress. Based on the experimental electron-density map, there is one molecule in the asymmetric unit, consistent with the prediction by Matthews cell-content analysis.

Table 1. Statistics for X-ray diffraction data sets and phasing.

The space group of the CfaA crystals is C2. All diffraction data sets were collected at beamline 22-BM, Argonne National Laboratory. Values in parentheses are for the outermost shells.

Data sets Native Pb Pt
Wavelength (Å) 0.98197 0.98197 0.89197
Resolution (Å) 50–2.03 (2.08–2.03) 30–1.77 (1.81–1.77) 50–2.80 (2.90–2.80)
Unit-cell parameters (Å, °) a = 103.60, b = 28.68, c = 90.60, β = 119.70 a = 102.12, b = 28.51, c = 90.04, β = 118.95 a = 102.04, b = 28.64, c = 90.41, β = 119.01
No. of observations 51359 138094 105508
No. of unique reflections 14999 (732) 22616 (1450) 5596 (202)
Average mosaicity (°) 0.22 0.20 0.20
R merge † 0.066 (0.433) 0.053 (0.394) 0.084 (0.205)
Completeness (%) 97.4 (72.9) 99.3 (97.9) 95.1 (69.4)
Average I/σ(I) 19.3 (2.7) 19.6 (2.2) 24.5 (4.6)
Multiplicity 3.4 (2.9) 3.3 (2.7) 6.4 (3.4)
†

R merge is defined as Inline graphic Inline graphic, where Ii(hkl) is the intensity of the ith observation of a reflection with Miller indices hkl and 〈I(hkl)〉 is the mean intensity for all measured I(hkl) and Friedel pairs.

Table 2. MIRAS phasing statistics.

  Sites x y z Occupancy B (Å2) PPcentric † PPacentric
Pt derivative 1 0.3984 0.3933 0.4867 0.7739 59.1 0.83 0.76
Pb derivative 1 0.9701 0.3316 0.3011 0.0761 15.9 0.38 0.41
2 0.4647 0.1313 0.0253 0.2622 14.9    
Resolution (Å) 10.22 6.41 4.99 4.23 3.73 3.37 3.10 2.89 Total
Mean figure of merit 0.61 0.64 0.58 0.54 0.50 0.44 0.43 0.40 0.49
†

Phasing power (PP) is defined as 〈f H〉/residual, where 〈f H〉 is the root-mean-square (r.m.s.) of the structure-factor contribution to amplitudes from heavy atoms in the derivative and residual is the r.m.s. of the lack-of-closure error.

Acknowledgments

The authors wish to thank the beamline staff of the SER-CAT at APS, ANL for their assistance in data collection. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, by a grant from the Trans-NIH/FDA Intramural Biodefense Program (to DX), by the US Army Military Infectious Diseases Research Program Work Unit Number A0307 (to SJS) and by the Henry M. Jackson Foundation for the Advancement of Military Medicine (SJS).

References

  1. Adams, P. D. et al. (2010). Acta Cryst. D66, 213–221.
  2. Anantha, R. P., McVeigh, A. L., Lee, L. H., Agnew, M. K., Cassels, F. J., Scott, D. A., Whittam, T. S. & Savarino, S. J. (2004). Infect. Immun. 72, 7190–7201. [DOI] [PMC free article] [PubMed]
  3. Bao, R., Nair, M. K. M., Tang, W.-K., Esser, L., Sadhukhan, A., Holland, R. L., Xia, D. & Schifferli, D. M. (2013). Proc. Natl Acad. Sci. USA, 110, 1065–1070. [DOI] [PMC free article] [PubMed]
  4. Black, R. E. (1990). Rev. Infect. Dis. 12, S73–S79. [DOI] [PubMed]
  5. Chapman, D. A., Zavialov, A. V., Chernovskaya, T. V., Karlyshev, A. V., Zav’yalova, G. A., Vasiliev, A. M., Dudich, I. V., Abramov, V. M., Zav’yalov, V. P. & MacIntyre, S. (1999). J. Bacteriol. 181, 2422–2429. [DOI] [PMC free article] [PubMed]
  6. Choudhury, D., Thompson, A., Stojanoff, V., Langermann, S., Pinkner, J., Hultgren, S. J. & Knight, S. D. (1999). Science, 285, 1061–1066. [DOI] [PubMed]
  7. Evans, D. G., Silver, R. P., Evans, D. J. Jr, Chase, D. G. & Gorbach, S. L. (1975). Infect. Immun. 12, 656–667. [DOI] [PMC free article] [PubMed]
  8. Gaastra, W. & Svennerholm, A. M. (1996). Trends Microbiol. 4, 444–452. [DOI] [PubMed]
  9. Hibberd, M. L., McConnell, M. M., Willshaw, G. A., Smith, H. R. & Rowe, B. (1991). J. Gen. Microbiol. 137, 1963–1970. [DOI] [PubMed]
  10. Huilan, S., Zhen, L. G., Mathan, M. M., Mathew, M. M., Olarte, J., Espejo, R., Khin Maung, U., Ghafoor, M. A., Khan, M. A., Sami, Z. & Sutton, R. G. (1991). Bull. World Health Organ. 69, 549–555. [PMC free article] [PubMed]
  11. Isidean, S. D., Riddle, M. S., Savarino, S. J. & Porter, C. K. (2011). Vaccine, 29, 6167–6178. [DOI] [PubMed]
  12. Kuehn, M. J., Ogg, D. J., Kihlberg, J., Slonim, L. N., Flemmer, K., Bergfors, T. & Hultgren, S. J. (1993). Science, 262, 1234–1241. [DOI] [PubMed]
  13. Li, Y.-F., Poole, S., Nishio, K., Jang, K., Rasulova, F., McVeigh, A., Savarino, S. J., Xia, D. & Bullitt, E. (2009). Proc. Natl Acad. Sci. USA, 106, 10793–10798. [DOI] [PMC free article] [PubMed]
  14. Li, Y.-F., Poole, S., Rasulova, F., McVeigh, A. L., Savarino, S. J. & Xia, D. (2007). J. Biol. Chem. 282, 23970–23980. [DOI] [PubMed]
  15. Lusty, C. J. (1999). J. Appl. Cryst. 32, 106–112.
  16. Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. [DOI] [PubMed]
  17. Nuccio, S. P. & Bäumler, A. J. (2007). Microbiol. Mol. Biol. Rev. 71, 551–575. [DOI] [PMC free article] [PubMed]
  18. Otwinowski, Z. & Minor, W. (1997). Methods Enzymol. 276, 307–326. [DOI] [PubMed]
  19. Poole, S. T., McVeigh, A. L., Anantha, R. P., Lee, L. H., Akay, Y. M., Pontzer, E. A., Scott, D. A., Bullitt, E. & Savarino, S. J. (2007). Mol. Microbiol. 63, 1372–1384. [DOI] [PubMed]
  20. Sakellaris, H., Balding, D. P. & Scott, J. R. (1996). Mol. Microbiol. 21, 529–541. [DOI] [PubMed]
  21. Sakellaris, H. & Scott, J. R. (1998). Mol. Microbiol. 30, 681–687. [DOI] [PubMed]
  22. Sauer, F. G., Fütterer, K., Pinkner, J. S., Dodson, K. W., Hultgren, S. J. & Waksman, G. (1999). Science, 285, 1058–1061. [DOI] [PubMed]
  23. Soto, G. E. & Hultgren, S. J. (1999). J. Bacteriol. 181, 1059–1071. [DOI] [PMC free article] [PubMed]
  24. Teng, T.-Y. & Moffat, K. (1998). J. Appl. Cryst. 31, 252–257.
  25. Terwilliger, T. C. (2003). Methods Enzymol. 374, 22–37. [DOI] [PubMed]
  26. Wennerås, C. & Erling, V. (2004). J. Health Popul. Nutr. 22, 370–382. [PubMed]

Articles from Acta Crystallographica. Section F, Structural Biology Communications are provided here courtesy of International Union of Crystallography

RESOURCES